• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:05:17 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    8-K
    false000176230300017623032025-05-082025-05-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 08, 2025

     

     

    AVITA Medical, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39059

    85-1021707

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    28159 Avenue Stanford

    Suite 220

     

    Valencia, California

     

    91355

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 661 367-9170

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    RCEL

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 8, 2025, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description of Exhibit

    99.1

     

    Press release, dated May 8, 2025, issued by AVITA Medical, Inc.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    AVITA Medical, Inc.

     

     

     

     

    Date:

    May 8, 2025

    By:

    /s/ David O'Toole

     

     

     

    David O'Toole
    Chief Financial Officer

     

     


    Get the next $RCEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVITA Medical Successfully Completes Australian Equity Raise

    Private placement of approximately 17.2 million new CHESS Depositary Interests ("New CDIs") quoted on the Australian Securities Exchange (ASX)Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private placement (the "Placement") to institutional and professional investors in Australia to raise an approximate gross amount of US$15 million (approximately A$23 millio

    8/12/25 8:30:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical to Host Investor Webinar Briefing

    VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 14, 2025, at 9 AM Australian Eastern Daylight Time (August 13 at 4 PM U.S. Pacific Standard Time). The webinar presentation will cover financial and business results from our recent second-quarter 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via

    8/10/25 7:00:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation

    VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Results Commercial revenue of $18.4 million: Representing an increase of approximately 21% compared to the same period in 2024.Net loss improvement: Net loss for Q2 2025 was $9.9 million, or a loss of $0.38 per basic and diluted share, an improvement from a net loss of $15.4 million, or a loss of $0.60 per basic and diluted share, in Q2 2024.Operating expense reduction: Total operating expenses decreased to $26.1 million i

    8/7/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcnamara Robert bought $50,000 worth of shares (10,000 units at $5.00), increasing direct ownership by 15% to 76,771 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/20/25 6:11:04 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $9,620 worth of shares (2,000 units at $4.81), increasing direct ownership by 7% to 29,657 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/12/25 4:30:15 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Tarnoff Michael E

    3 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/6/25 5:00:05 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avita Medical downgraded by BTIG Research with a new price target

    BTIG Research downgraded Avita Medical from Neutral to Sell and set a new price target of $3.00

    8/8/25 8:17:21 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Avita Medical with a new price target

    D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

    12/24/24 7:10:27 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical downgraded by BTIG Research

    BTIG Research downgraded Avita Medical from Buy to Neutral

    4/11/24 7:58:22 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcnamara Robert bought $50,000 worth of shares (10,000 units at $5.00), increasing direct ownership by 15% to 76,771 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/20/25 6:11:04 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $9,620 worth of shares (2,000 units at $4.81), increasing direct ownership by 7% to 29,657 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    8/12/25 4:30:15 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    3/10/25 4:30:06 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    SEC Filings

    View All

    Avita Medical Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    8/18/25 5:16:38 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    8/12/25 8:20:28 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Avita Medical Inc.

    S-8 - AVITA Medical, Inc. (0001762303) (Filer)

    8/8/25 4:35:54 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    2/13/24 4:58:57 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    1/26/24 4:23:41 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

    SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

    2/9/23 11:07:47 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Financials

    Live finance-specific insights

    View All

    AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation

    VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Results Commercial revenue of $18.4 million: Representing an increase of approximately 21% compared to the same period in 2024.Net loss improvement: Net loss for Q2 2025 was $9.9 million, or a loss of $0.38 per basic and diluted share, an improvement from a net loss of $15.4 million, or a loss of $0.60 per basic and diluted share, in Q2 2024.Operating expense reduction: Total operating expenses decreased to $26.1 million i

    8/7/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical to Announce Second Quarter 2025 Financial Results

    VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2025 financial results after the close of the U.S. financial markets on Thursday, August 7, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir

    7/28/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Reports First Quarter 2025 Financial Results

    VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

    5/8/25 4:03:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    View All

    AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

    Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, announced today the appointment to its Board of Directors (the "Board") of Michael Tarnoff, MD, FACS, as a non-executive Director, effective August 6, 2025. Dr. Tarnoff's appointment comes as the Company fu

    8/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical's Acute Wound Care Showcase 2025 Streams Live Today

    VALENCIA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, is hosting its Acute Wound Care Showcase 2025 virtually today, May 13, 2025, at 11:00 a.m. Pacific Time. Attendees will hear directly from leading burn and trauma clinicians using AVITA Medical's technologies, as well as from patients who have personally benefited from treatment following traumatic injuries. The event will also feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs, who will provide an overview of AVITA Medica

    5/13/25 9:00:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

    VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

    7/1/24 4:05:00 PM ET
    $RCEL
    $AMRS
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials